MX2022005305A - Formulacion oral de x842. - Google Patents
Formulacion oral de x842.Info
- Publication number
- MX2022005305A MX2022005305A MX2022005305A MX2022005305A MX2022005305A MX 2022005305 A MX2022005305 A MX 2022005305A MX 2022005305 A MX2022005305 A MX 2022005305A MX 2022005305 A MX2022005305 A MX 2022005305A MX 2022005305 A MX2022005305 A MX 2022005305A
- Authority
- MX
- Mexico
- Prior art keywords
- oral formulation
- relates
- egerd
- surfactant
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La invención se refiere a una formulación oral de liberación inmediata de X842 que comprende sólo cantidades limitadas de agente tensioactivo. La invención también se refiere al uso de la formulación oral en el tratamiento de enfermedades inflamatorias gastrointestinales o enfermedades relacionadas con el ácido gástrico, en particular enfermedad por reflujo gastroesofágico erosivo (eGERD).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE1951255 | 2019-11-04 | ||
PCT/EP2020/080877 WO2021089580A1 (en) | 2019-11-04 | 2020-11-04 | Oral formulation of x842 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022005305A true MX2022005305A (es) | 2022-08-16 |
Family
ID=73131746
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022005305A MX2022005305A (es) | 2019-11-04 | 2020-11-04 | Formulacion oral de x842. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20220362223A1 (es) |
EP (1) | EP4054537B1 (es) |
JP (1) | JP2023500904A (es) |
KR (1) | KR20220097431A (es) |
CN (1) | CN114901262A (es) |
AU (1) | AU2020377451A1 (es) |
BR (1) | BR112022008384A2 (es) |
CA (1) | CA3156073A1 (es) |
ES (1) | ES2949232T3 (es) |
IL (1) | IL292682A (es) |
MX (1) | MX2022005305A (es) |
WO (1) | WO2021089580A1 (es) |
ZA (1) | ZA202205756B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023079094A1 (en) | 2021-11-05 | 2023-05-11 | Cinclus Pharma Holding AB (publ) | Polymorphs of the hydrochloride salt of linaprazan glurate |
WO2023184282A1 (en) * | 2022-03-30 | 2023-10-05 | Guizhou Sinorda Biomedicine Co., Ltd | X842 formulation |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9801526D0 (sv) | 1998-04-29 | 1998-04-29 | Astra Ab | New compounds |
US20090092658A1 (en) * | 2007-10-05 | 2009-04-09 | Santarus, Inc. | Novel formulations of proton pump inhibitors and methods of using these formulations |
CN101002939A (zh) * | 2007-01-12 | 2007-07-25 | 广东华南药业有限公司 | 一类治疗与胃酸有关疾病的药物组合制剂 |
FI20086158A0 (fi) * | 2008-12-03 | 2008-12-03 | Mikael Dahlstroem | Imidatsopyridiinijohdannaiset |
CN101816641B (zh) * | 2010-03-11 | 2012-04-04 | 沈阳亿灵医药科技有限公司 | 一种奥美拉唑速释固体制剂及其制备方法 |
CN102294031B (zh) * | 2011-09-07 | 2013-02-20 | 沈阳亿灵医药科技有限公司 | 含质子泵抑制剂、nsaid和抗酸剂的药物制剂 |
CN103860584B (zh) * | 2014-02-25 | 2015-09-30 | 厦门恩成制药有限公司 | 一种奥美拉唑碳酸氢钠胶囊的制作方法 |
JP6910950B2 (ja) * | 2015-01-12 | 2021-07-28 | エンテリス・バイオファーマ・インコーポレイテッドEnteris Biopharma,Inc. | 固形経口剤形 |
CN106619520B (zh) * | 2016-12-29 | 2019-08-06 | 南京海融制药有限公司 | 一种右兰索拉唑钠的干混悬剂及其制备方法 |
-
2020
- 2020-11-04 WO PCT/EP2020/080877 patent/WO2021089580A1/en unknown
- 2020-11-04 CN CN202080076863.0A patent/CN114901262A/zh active Pending
- 2020-11-04 CA CA3156073A patent/CA3156073A1/en active Pending
- 2020-11-04 KR KR1020227017919A patent/KR20220097431A/ko unknown
- 2020-11-04 EP EP20801237.7A patent/EP4054537B1/en active Active
- 2020-11-04 JP JP2022526056A patent/JP2023500904A/ja active Pending
- 2020-11-04 US US17/774,207 patent/US20220362223A1/en active Pending
- 2020-11-04 ES ES20801237T patent/ES2949232T3/es active Active
- 2020-11-04 AU AU2020377451A patent/AU2020377451A1/en active Pending
- 2020-11-04 BR BR112022008384A patent/BR112022008384A2/pt unknown
- 2020-11-04 MX MX2022005305A patent/MX2022005305A/es unknown
-
2022
- 2022-05-02 IL IL292682A patent/IL292682A/en unknown
- 2022-05-16 ZA ZA2022/05756A patent/ZA202205756B/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2023500904A (ja) | 2023-01-11 |
US20220362223A1 (en) | 2022-11-17 |
KR20220097431A (ko) | 2022-07-07 |
BR112022008384A2 (pt) | 2022-07-12 |
EP4054537A1 (en) | 2022-09-14 |
AU2020377451A1 (en) | 2022-05-26 |
CN114901262A (zh) | 2022-08-12 |
CA3156073A1 (en) | 2021-05-14 |
EP4054537B1 (en) | 2023-06-07 |
ES2949232T3 (es) | 2023-09-26 |
IL292682A (en) | 2022-07-01 |
ZA202205756B (en) | 2023-10-25 |
WO2021089580A1 (en) | 2021-05-14 |
EP4054537C0 (en) | 2023-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202205756B (en) | Oral formulation of x842 | |
MX2020008271A (es) | Inhibidor de fap. | |
PH12019500932A1 (en) | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh | |
PH12018501037A1 (en) | Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease | |
NZ732241A (en) | A modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders | |
CA3045666A1 (en) | Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices | |
WO2018077944A3 (en) | 4,5-annulated 1,2,4-triazolones | |
MY157661A (en) | Bendamustine pharmaceutical compositions | |
EA201890767A1 (ru) | C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений | |
WO2007147019A3 (en) | Il-17 and il-23 antagonists and methods of using the same | |
EA201892202A1 (ru) | Способы лечения холестатических заболеваний | |
MX2017009417A (es) | Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas. | |
MX2016014771A (es) | Forma de dosificacion oralmente desintegrante para administracion de avanafil, y metodos de fabricacion y uso asociados. | |
UA94036C2 (ru) | Фармацевтическая композиция бендамустина, предназначенная для лиофилизации | |
MX2022006768A (es) | Formulaciones/composiciones que comprenden un inhibidor de btk. | |
MX2020001404A (es) | Dihidrooxadiazinonas. | |
MX2022006817A (es) | Formulaciones/composiciones que comprenden un inhibidor de btk. | |
EA202191955A1 (ru) | Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы | |
MX2020004981A (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3. | |
TW200728281A (en) | Novel N-sulfamoyl-piperidineamides for the prophylaxis or treatment of obesity and related conditions | |
MX2011011618A (es) | Agentes terapeuticos 713. | |
WO2015055898A3 (en) | Compositions comprising phosphodiesterase inhibitors for use in the treatment of a solid tumor in a human patient | |
CO2017007691A2 (es) | Inhibidores de la β-secretasa derivados de la 5-amino-3-(5-(3-isoxazol-5-il)-3-(fluorometil)-6,6-dimetil-1-(metilimino)-3,6-dihidro-2h-1,4-tiazina o 5-amino-3-(5-(1h-1,2,3-triazol-4-il)-2-fluorofenil)-6,6-dimetil-1-(metilimino)-3,6-dihidro-2h-1,4-tiazina composiciones que los comprenden y métodos de elaboración | |
WO2010117756A3 (en) | Substituted benzimidazole pharmaceutical formulations | |
PH12020500204A1 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic disease |